Osteoporosis in patients with schizophrenia

American Journal of Psychiatry

Volumn 162, Issue 1, 2005, Pages 162-167

  Hummer, Martina ^a   Malik, Peter ^b   Gasser, Rudolf W ^b   Hofer, Alex ^b   Kemmler, Georg ^b   Naveda, Roy Cesar Moncayo ^b   Rettenbacher, Maria A ^b   Fleischhacker, W Wolfgang ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXY VITAMIN D3; COLECALCIFEROL DERIVATIVE; NEUROLEPTIC AGENT; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HOSPITAL PATIENT; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTPATIENT; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BONE DENSITY; CALCIFEDIOL; COMORBIDITY; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; SCHIZOPHRENIA; SEX DISTRIBUTION; SEX FACTORS;

EID: 11844298340     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.1.162     Document Type: Article

References (35)

1. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57:485-491
2. Abraham G, Halbreich U, Friedman RH, Josiassen RC: Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 2003; 59:17-18
3. Parfitt AM: Quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif Tissue Int 1979; 28:1-5
4. Wolinsky-Friedland M: Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am 1995; 24:395-420
5. Johnston CC, Melton LJ, Lindsdy R: Clinical indications for bone mass measurements: report of the Scientific Advisory Committee of the National Osteoporosis Foundation. J Bone Miner Res 1989; 4(suppl 2):1-28
6. Glaser DL, Kaplan FS: Osteoporosis: definition and clinical presentation. Spine 1997; 22(24 suppl):12S-16S
7. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28:53-67
8. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW: Decreased bone density in hyperprolactinemic women. N Engl J Med 1980; 303:1511-1514
9. Halbreich U, Palter S: Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996; 22:447-454
10. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH: Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993; 150:1408-1410
11. Cantor-Graae E, Nordstrom LG, McNeil TF: Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Bull 2001; 48:69-82
12. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D: Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002; 62:743-755
13. DeLeon J, Verghese C, Tracy JI, Josiassen RC, Simpson GM: Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biol Psychiatry 1994; 35:408-419
14. Weltgesundheitsorganisation: Internationale Klassifikation psychischer Störungen: ICD 10. Bern, Germany, Verlag Hans Huber, 1993
15. World Health Organization: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Geneva, WHO, 1998, pp 5-6
16. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
17. White L, Harvey PD, Opler LA, Lindenmayer JP (PANSS Study Group): Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: a multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology 1997; 3:263-274
18. Schweiger U, Weber B, Deuschle M, Heuser I: Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am J Psychiatry 2000; 157:118-120
19. Bergemann N, Auler B, Parzer P, Resch F, Mundt C, Ziegler R, Seibel M: High bone turnover but normal bone mineral density in women with schizophrenia (abstract). Bone 2001; 28:248
20. Häfner H, Maurer K, Loffler W, Fatkenheuer B, An der Heiden W, Riecher-Rössler A, Behrens S, Gattaz WF: The epidemiology of early schizophrenia: influence of age and gender on onset and early course. Br J Psychiatry 1994; 23:29-38
21. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64:761-766
22. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929-1936
23. Webb AR, Kline L, Holick MF: Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67:373-378
24. Holick MF: Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 1995; 61(3 suppl):638S-645S
25. Sherman S: Preventing and treating osteoporosis: strategies at the millennium. Ann NY Acad Sci 2001; 949:188-197
26. Watts NB: Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results. J Reprod Med 2002; 47(1 suppl):82-92
27. Ovesen L: Vitamin therapy in the absence of obvious deficiency: what is the evidence? Drugs 1984; 27:148-170
28. Rodrigues-Martinez MA, Garcia-Cohen EC: Role of Ca(2+) and vitamin D in the prevention and treatment of osteoporosis. Pharmacol Ther 2002; 93:37-49
29. Kanis JA (WHO Study Group): Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994; 4:368-381
30. WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 1994; 843:1-129
31. Cooper C, Aihie A: Osteoporosis: recent advances in pathogenesis and treatment. Q J Med 1994; 87:203-209
32. Kanis JA, Johnell O, Oden A, DeLae C, Jonsson B, Dawson A: Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30:251-258
33. Garnero P, Sornay-Rendu E, Clustrat B, Delmas PD: Biochemical markers of bone turnover, endogenous hormone and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15:1526-1536
34. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (Committee of Scientific Advisors of the International Osteoporosis Foundation): The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; 11 (suppl 6):S2-S17
35. Kanis JA, McCloskey EV: Evaluation of the risk of hip fracture. Bone 1996; 18(3 suppl):127S-132S